journal
MENU ▼
Read by QxMD icon Read
search

Ecancermedicalscience

journal
https://www.readbyqxmd.com/read/30483361/the-impact-of-tobacco-tax-law-implementation-on-pancreatic-cancer-mortality-in-mexico-1999-2015
#1
EDITORIAL
Eduardo Hernández-Garduño
Among the multiple aetiologies identified for pancreatic cancer (PC), cigarette smoking and diabetes are considered "moderate risk factors". Analysis of PC mortality trends is important as changes in incidence and mortality of this tumour can be partially attributable to changes in smoking patterns. A recent Mexican study examined PC mortality trends and showed a favourable trend from 2000 to 2014 [1]. However, the impact of new tobacco tax/laws which were implemented in Mexico in 2007/2008 was not assessed in this study...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483360/information-sources-and-online-information-seeking-behaviours-of-cancer-patients-in-singapore
#2
Gek Phin Chua, Hiang Khoon Tan, Mihir Gandhi
The aim of this study was to investigate the prevalence of Internet usage among cancer patients in seeking health-related information and the type of information sought. Sources of information received from, preferences for information sources and the perceived usefulness of information from these sources were also examined in this study. A self-administered questionnaire was used to evaluate the information needs of patients undergoing cancer treatment. The questionnaire also evaluated the current source and preferred source of information as well as their online information seeking behaviours...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483359/high-tumour-burden-delayed-diagnosis-and-history-of-cardiovascular-disease-may-be-associated-with-carcinoid-heart-disease
#3
Carolina Alves, Marcella Mesquita, Carolina Silva, Maria Soeiro, Ludhmila Hajjar, Rachel P Riechelmann
Background: Patients with carcinoid syndrome (CS) may present carcinoid heart disease (CHD) but prognostic factors are not entirely understood. Patients and Methods: Retrospective study of patients with metastatic neuroendocrine tumours (NETs) and CS and/or abnormal 24-hour-urinary 5-hydroxiindolacetic acid. CHD was defined as moderate to severe tricuspid or pulmonary regurgitation in the echocardiogram. Results: The frequency of CHD among 42 patients was 38% (95% confidence interval [CI]: 23%-54%)...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483358/identifying-barriers-and-finding-solutions-to-implement-best-practices-for-cancer-surgery-at-maputo-central-hospital-mozambique
#4
Atílio Morais, Matchecane Cossa, Adriano Tivane, Jotamo Come, Volodimir Venetsky, Fernando Torres, Victor Pacheco, Miguel Reyes, Germano Pires, Mariana Peyroteo, Satish Tulsidas, Ellen Baker, Moshin Sidat, Maria do Rosário O Martins, Lúcio Lara Santos
Purpose: The aim of this study was to assess the surgical resources and surgical oncology team skills at the Surgical Department of Maputo Central Hospital (MCH) in Mozambique in order to define an educational program to support surgical oncology practice. Methods: From January 2017 to December 2017, a general evaluation of the resources of MCH was carried out, as well as its offerings in oncological care in different services. Data were obtained by reviewing documents, visiting surgical services and interviewing key-informants and others informally...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483357/from-science-to-real-life-oncology-the-ecco-2018-european-cancer-summit-7-9-september-2018-vienna-austria
#5
Sarah Liptrott
The European CanCer Organisation (ECCO) held its first European Cancer Summit in Vienna, Austria, from 7-9 September 2018. The summit, 'From Science to Real-life Oncology', attracted over 370 participants from across the globe. The aim of the event was connecting science with real life through policy evolution. A broad range of stakeholders attended the event including representatives of ECCO Member Societies, healthcare professionals, pharmaceutical company representatives, patient organisations including patient advocates, commercial providers to the healthcare sector, EU and national/regional government officials as well as academic researchers and regulatory professionals...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483356/thromboembolic-events-in-patients-with-advanced-stage-non-small-cell-lung-cancer-treated-with-platinum-based-chemotherapy-a-prospective-observational-study
#6
Amit Joshi, Shruti Kate, Vanita Noronha, Vijay Patil, Vaishakhi Trivedi, Supriya Goud, Sucheta More, Sandeep Bhairva, Kumar Prabhash
Objectives: Cancer is frequently complicated by thromboembolic events (TEs). We aimed to determine the incidence of TEs in lung cancer patients treated with platinum-based chemotherapy and study patients' baseline and treatment attributes correlating with its onset. Materials and methods: Advanced lung cancer patients started on platinum-based chemotherapy were evaluated at baseline and during routine visits for the development of TEs. The duration of follow-up was 4 weeks from the last chemotherapy...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483355/regorafenib-adjusted-dose-for-chilean-patients-with-chemoresistant-metastatic-colorectal-cancer-a-case-series
#7
José Luis Leal, Juan Briones, María Elisa Herrera, Bettina Müller, Bruno Nervi, Sebastián Mondaca
Background: Regorafenib is a therapeutic alternative for patients with metastatic colorectal cancer (MCRC) resistant to conventional therapies. The reported toxicity is relevant and there is no data on Latin American patients. The objective was to evaluate the overall survival (OS), progression-free survival (PFS) and quality of life (QoL) in a prospective cohort of Latin American patients treated with an adjusted dose of regorafenib. Methods: We prospectively recruited patients with MCRC that progressed to standard therapy...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483354/clinical-decision-making-in-postmastectomy-radiotherapy-in-node-negative-breast-cancer
#8
REVIEW
Rodrigo Barrientos, Suraj Samtani, Michael Frelinghuysen, Camilo Sotomayor, Juan Guillermo Gormaz, Mauricio Burotto
For decades, postmastectomy radiotherapy (PMRT) has been recommended for node positive [N(+)] breast cancer patients; nevertheless, the beneficial effect of PMRT for treatment of node negative [N(-)] disease remains under discussion. Nowadays, the biology of breast cancer and the risk factors (RFs) for locoregional failure (LRF) must be included in the decision on whether or not to carry out PMRT. For these reasons, the present review aims to evaluate the rationale use of PMRT in N(-) patients and discuss which subgroups may further benefit from the treatment in present times where the decision must be personalised, according to the RFs of locoregional recurrence (LRR)...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483353/what-information-do-cancer-patients-want-and-how-well-are-their-needs-being-met
#9
Gek Phin Chua, Hiang Khoon Tan, Mihir Gandhi
The goal of this study is to determine the type of information cancer patients need and to measure the extent to which these information needs are met by measuring patients' levels of satisfaction. A self-administered questionnaire developed through extensive literature reviews was pilot tested on 11 cancer patients using convenience sampling in a large ambulatory cancer centre in Singapore. All eligible patients attending the centre during a 5-month period were invited to complete the 76-item survey that had been designed to evaluate self-reported information needs and level of satisfaction with the information received while undergoing cancer treatment...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30483352/use-of-peg-asparaginase-in-a-case-of-hepatosplenic-%C3%AE-%C3%AE-t-cell-lymphoma-with-long-term-remission-after-stem-cell-transplantation
#10
Kai Sun, Cesar Gentille Sanchez, Sai Ravi Pingali, Swaminathan Iyer
Hepatosplenic γδ T-cell lymphoma (HSTCL) is a rare aggressive peripheral T-cell lymphoma. Prognosis is usually poor with a median survival between 8 and 16 months after traditional chemotherapy. Stem cell transplantation (SCT) is promising and with a more intense induction regimen, has yielded positive results. We report the use of pegylated-asparaginase (PEG-asparaginase) along with a conventional anthracycline-containing regimen in a 51-year-old male who was diagnosed with HSTCL, achieved a complete remission, and subsequently underwent peripheral blood SCT and remained in remission at the time of this case report...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263062/highlights-from-the-2018-win-symposium-25-26-june-2018-paris-designing-the-future-of-precision-oncology
#11
Will Davies
The Worldwide Innovative Networking (WIN) Symposium is the annual gathering of WIN consortium members from across the globe, representing academic institutions, pharmaceutical partners, technology companies and charitable organisations, to discuss ongoing research and the latest developments in precision oncology. The symposium held in Paris, France on 25-26 June was structured into five plenary sessions, two open forums and poster presentations. This year marked the 10th anniversary of the consortium, and the programme anchored itself with retrospectives of recent breakthroughs in personalised medicine, programme sessions reviewing the iterative design of trials in precision oncology at present, and the future of implementing personalised medicine initiatives in US and EU healthcare systems for the maximum patient benefit...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263061/inspiration-innovation-and-integration-highlights-from-the-third-icpcn-conference-on-children-s-palliative-care-30-may-to-2-june-2018-durban-south-africa
#12
Julia Downing, Sue Boucher, Julia Ambler, Tracey Brand, Zodwa Sithole, Busi Nkosi, Michelle Meiring, Elizabeth Gwyther, Lorna Sithole, Barbara Steel, Alex Daniels
The International Children's Palliative Care Network (ICPCN) held its third international conference on children's palliative care in Durban, South Africa, from May 30 2018 to 2 June 2018. The conference-inspiration, innovation and integration-brought together 250 participants from 41 countries and was held in conjunction with local partners-Umduduzi Hospice Care for Children, Palliative Treatment for Children South Africa (Patch SA) and the Hospice and Palliative Care Association of South Africa. It built on national and global developments in palliative care such as its inclusion in Universal health coverage (UHC), the Lancet Commission report on pain and palliative care and the sustainable development goals (SDGs), and aimed to raise the profile of children's palliative care in KwaZulu-Natal (KZN) and nationally...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263060/pre-pro-and-synbiotics-in-cancer-prevention-and-treatment-a-review-of-basic-and-clinical-research
#13
REVIEW
Alasdair J Scott, Claire A Merrifield, Jessica A Younes, Elizabeth P Pekelharing
There is a growing appreciation of the role of the human microbiota in the pathophysiology of cancer. Pre-, pro- and synbiotics are some of the best evidenced means of manipulating the microbiota for therapeutic benefit and their potential role in the prevention and treatment of cancer has garnered significant interest. In this review, we discuss how these agents may have oncosuppressive effects by maintaining intestinal barrier function, immunomodulation, metabolism and preventing host cell proliferation. We highlight the epidemiological and trials-based evidence supporting a role for pre-, pro- and synbiotics in the prevention of cancer...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263059/gut-microbiota-chemotherapy-and-the-host-the-influence-of-the-gut-microbiota-on-cancer-treatment
#14
REVIEW
Anna Louise Pouncey, Alasdair James Scott, James Leslie Alexander, Julian Marchesi, James Kinross
The gut microbiota exists in a dynamic balance between symbiosis and pathogenesis and can influence almost any aspect of host physiology. Growing evidence suggests that the gut microbiota not only plays a key role in carcinogenesis but also influences the efficacy and toxicity of anticancer therapy. The microbiota modulates the host response to chemotherapy via numerous mechanisms, including immunomodulation, xenometabolism and alteration of community structure. Furthermore, exploitation of the microbiota offers opportunities for the personalisation of chemotherapeutic regimens and the development of novel therapies...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263058/moving-on-from-metchnikoff-thinking-about-microbiome-therapeutics-in-cancer
#15
REVIEW
Saman Maleki Vareki, Ryan M Chanyi, Kamilah Abdur-Rashid, Liam Brennan, Jeremy P Burton
Precision medicine now needs to also consider the microbiome in oncology treatment. Ingested substances, whether they are a carcinogenic or therapeutic agent, will likely come into contact with the microbiota. Even those delivered extra-intestinally can be influenced beyond xenobiotic metabolism by biochemical factors associated with the microbiota or by an immunological predisposition created by the microbiome. We need to undertake one of the largest paradigm shifts to ever occur in medicine, that is, every drug or ingested substance needs to be re-evaluated for its pharmacological effect post-microbiome interaction...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263057/lung-cancer-a-new-frontier-for-microbiome-research-and-clinical-translation
#16
REVIEW
Luis Aj Mur, Sharon A Huws, Simon Js Cameron, Paul D Lewis, Keir E Lewis
The lung microbiome has been shown to reflect a range of pulmonary diseases-for example: asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Studies have now begun to show microbiological changes in the lung that correlate with lung cancer (LC) which could provide new insights into lung carcinogenesis and new biomarkers for disease screening. Clinical studies have suggested that infections with tuberculosis or pneumonia increased the risk of LC possibly through inflammatory or immunological changes...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263056/colorectal-carcinogenesis-an-archetype-of-gut-microbiota-host-interaction
#17
REVIEW
James L Alexander, Alasdair J Scott, Anna L Pouncey, Julian Marchesi, James Kinross, Julian Teare
Sporadic colorectal cancer (CRC) remains a major cause of worldwide mortality. Epidemiological evidence of markedly increased risk in populations that migrate to Western countries, or adopt their lifestyle, suggests that CRC is a disease whose aetiology is defined primarily by interactions between the host and his environment. The gut microbiome sits directly at this interface and is now increasingly recognised as a modulator of colorectal carcinogenesis. Bacteria such as Fusobacterium nucleatum and Escherichia coli ( E...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30263055/the-implementation-of-omics-technologies-in-cancer-microbiome-research
#18
REVIEW
Benjamin H Mullish, Laura S Osborne, Julian R Marchesi, Julie Ak McDonald
Whilst the interplay between host genetics and the environment plays a pivotal role in the aetiopathogenesis of cancer, there are other key contributors of importance as well. One such factor of central and growing interest is the contribution of the microbiota to cancer. Even though the field is only a few years old, investigation of the 'cancer microbiome' has already led to major advances in knowledge of the basic biology of cancer risk and progression, opened novel avenues for biomarkers and diagnostics, and given a better understanding of mechanisms underlying response to therapy...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30174725/surgery-for-brca-tp53-and-palb2-a-literature-review
#19
REVIEW
Chin-Vern Song, Soo-Hwang Teo, Nur Aishah Taib, Cheng-Har Yip
Introduction: The presence of a deleterious mutation, most commonly a BRCA mutation, has a tremendous impact on the management of breast cancer. We review the surgical management of BRCA mutation carriers, and two other potentially high-risk mutations, TP53 and PALB2. Methodology: A search was done on PubMed, limited to reviews and the English language only. The search terms used were ' BRCA ' or ' PALB2 ' or ' TP53 ' and 'surgery'. Fifteen articles were identified by searching and one article was obtained from other sources...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/30174724/quick-and-sustained-clinical-response-to-mek-inhibitor-i-in-a-nf1-patient-with-neurofibromas
#20
Honoré Papalia, Frédérique Audic, Gabriel Revon Rivière, Arnauld Verschuur, Nicolas André
Neurofibromatosis 1 (NF1) is an autosomal dominant tumour predisposition disorder with a birth incidence of about 1 in 2,700 and prevalence of 1 in 4,560. The NF1 gene codes for an ubiquitous protein: neurofibromin. Neurofibromin interacts with the proto-oncogene RAS to suppress tumour formation. Individuals with germline inactivation of the NF1 gene have a propensity to develop both benign and malignant tumours. We report the case of a 12-year-old child with NF1, diagnosed at the age of 15 months, for whom the clinical course has been marked by the appearance of multiple cutaneous and paraspinal neurofibromas responsible for impaired walking, motor deficiency and pain...
2018: Ecancermedicalscience
journal
journal
41838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"